aTyr Pharma Shares Drop After Company Announces New Phase 3 Trial for Efzofitimod
aTyr Pharma's stock fell about 15% in premarket trading after the company outlined plans for a new global Phase 3 trial of efzofitimod in pulmonary sarcoidosis. The company said it will file an investigational new drug application in June 2026 following FDA feedback, and that the randomized, double-blind, placebo-controlled study will enroll roughl…